Daniëlle Hendriks
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniëlle Hendriks.
Pediatric Pulmonology | 2014
Lieke Uijterschout; Marianne Nuijsink; Daniëlle Hendriks; Rimke Vos; Frank Brus
In adult CF patients iron deficiency (ID) is common and primarily functional due to chronic inflammation. No recent data are available on the cause of ID and iron deficiency anemia (IDA) in children with CF. Over the last decades onset of inflammation and pulmonary disease in children with CF is delayed by improved nutritional status. We questioned whether ID occurs in the same extent among children with CF as in adult CF patients. We therefore conducted a study to investigate the iron status of children with CF and to determine whether ID and IDA are associated with dietary iron intake, lung disease severity and Pseudomonas aeruginosa (PA) infection.
Journal of Crohns & Colitis | 2015
Sjoukje-Marije Haisma; Thijs Lijftogt; Angelika Kindermann; Gerard Damen; Lissy de Ridder; Johanna C. Escher; M. Luisa Mearin; Tim de Meij; Daniëlle Hendriks; Elvira K. George; Thalia Hummel; Obbe F. Norbruis; Patrick F. van Rheenen
BACKGROUND AND AIMS Methotrexate [MTX] is an immunomodulating drug that can be used to maintain remission in patients with Crohns disease [CD], but data on efficacy and tolerability in children and teenagers are scarce. We evaluated the long-term efficacy and tolerability of MTX monotherapy after thiopurine therapy in paediatric CD patients. METHODS A multicenter cohort of paediatric MTX users who stopped thiopurines due to ineffectiveness or intolerance between 2002 and 2012 were included and followed for at least 12 months. Relapse-free use was defined as steroid and biologics-free clinical remission after the introduction of MTX, and included intentional discontinuation of successful therapy before the end of the observation period. RESULTS A total of 113 patients with CD in remission were followed while on MTX monotherapy, of whom 75 [66%] had failed on thiopurines and 38 [34%] had stopped thiopurines due to side effects. Median age at the introduction of MTX was 14 years [range 7 to 17], and 93% used the subcutaneous route. Kaplan-Meier analysis showed that 52% of the study cohort were still in steroid- and biologics-free remission after 12 months of MTX monotherapy, with a difference that did not reach significance between thiopurine-intolerant and thiopurine-failing patients [p = 0.21, log-rank test]. CONCLUSIONS The findings of this cohort study suggest that MTX is an effective immunomodulator to maintain remission after stopping thiopurines. MTX maintenance should be considered before stepping up to anti-tumor necrosis factor alpha therapy. MTX is probably somewhat more effective in patients who stopped thiopurines due to side effects than in those who failed on thiopurines.
Inflammatory Bowel Diseases | 2015
Dwight A. Winter; Katarzyna Karolewska-Bochenek; Izabella Lazowska-Przeorek; Paolo Lionetti; M. Luisa Mearin; Sonny K. F. Chong; Eleftheria Roma-Giannikou; Jan Maly; Kaija-Leena Kolho; Ron Shaoul; Annamaria Staiano; Gerard Damen; Tim de Meij; Daniëlle Hendriks; Elvira K. George; Dan Turner; Johanna C. Escher
Background:Inflammatory bowel disease–unclassified (IBD-U) is diagnosed in ∼10% of pediatric and adolescent onset IBD patients. The EUROKIDS registry (2004) initiated by the Porto IBD working group of ESPGHAN prospectively monitors diagnostic workup of newly diagnosed pediatric and adolescent onset IBD patients. We aimed to describe diagnostic workup, phenotype, and change of diagnosis over time in pediatric IBD-U patients. Methods:Data were collected on children from 52 centers across 20 European countries and Israel, diagnosed with IBD from May 2005 through November 2013. Full endoscopy plus small bowel radiology was considered complete diagnostic workup. Participating centers reporting IBD-U patients were queried in 2014 for follow-up data. Results:IBD-U was the provisional first diagnosis in 265 of 3461 children (7.7%) (91/158 [58%] with pancolitis; 140 [53%] male), diagnosed more frequently under the age of 10 (median age 12.3 years, 89 [34%] under 10 years). Half (48%) had undergone complete diagnostic workup. Lack of small bowel radiology was the prevailing reason for incomplete workup. As a result of reinvestigations (endoscopy in 54%, radiology in 38%) during a median follow-up of 5.7 years (interquartile range, 2.5–7.8), a change in diagnosis from IBD-U to Crohns disease (12%) or ulcerative colitis (20%) was reported. Conclusions:Only half of patients reported as IBD-U in EUROKIDS had undergone complete diagnostic workup. Follow-up with reinvestigations resulted in a reduction of IBD-U rate to 5.6%. A diagnosis of IBD-U becomes less likely in case of complete diagnostic workup. Implementation of clear diagnostic criteria will further reduce the rate of IBD-U in the future.
Journal of Cystic Fibrosis | 2014
Lieke Uijterschout; Dorine W. Swinkels; Marjolijn D. Akkermans; Thomas Zandstra; Marianne Nuijsink; Daniëlle Hendriks; Cisca Hudig; Harrold Tjalsma; Rimke Vos; Johannes B. van Goudoever; Frank Brus
BACKGROUND The value of ferritin in the diagnosis of iron deficiency is limited in patients with CF since it increases in the presence of inflammation. We hypothesized that the soluble transferrin receptor (sTfR) and hepcidin may provide more information than ferritin in assessing iron status in children with CF. METHODS We analyzed sTfR and hepcidin in relation to conventional iron status indicators in 49 children with CF. RESULTS We found no differences in sTfR concentration between children with and those without ID. sTfR concentrations were within the normal range in all children. Hepcidin concentrations were low, and concentrations below the limit of detection were observed in 25% of the clinically stable children. CONCLUSION The sTfR is not useful to determine the iron status in this population, whereas hepcidin might serve as an early indicator of deficient iron stores in children with CF.
Journal of Crohns & Colitis | 2018
Anke Heida; A. C. Muller Kobold; John W. A. Rossen; Angelika Kindermann; Fredericus T. Kokke; T. G. J. de Meij; Obbe F. Norbruis; Rinse K. Weersma; M. Wessels; Thalia Hummel; H. Escher; H. van Wering; Daniëlle Hendriks; Luisa Mearin; Hendricus Groen; Henkjan J. Verkade; P. van Rheenen
Background and Aims Conventional follow-up of teenagers with inflammatory bowel diseases [IBD] is done during scheduled outpatient visits regardless of how well the patient feels. We designed a telemonitoring strategy for early recognition of flares and compared its efficacy with conventional follow-up. Methods We used a multicentre randomized trial in patients aged 10-19 years with IBD in clinical remission at baseline. Participants assigned to telemonitoring received automated alerts to complete a symptom score and send a stool sample for measurement of calprotectin. This resulted in an individual prediction for flare with associated treatment advice and test interval. In conventional follow-up the health check interval was left to the physicians discretion. The primary endpoint was cumulative incidence of disease flares. Secondary endpoints were percentage of participants with a positive change in quality-of-life and cost-effectiveness of the intervention. Results We included 170 participants [84 telemonitoring; 86 conventional follow-up]. At 52 weeks the mean number of face-to-face visits was significantly lower in the telemonitoring group compared to conventional follow-up [3.6 vs 4.3, p < 0.001]. The incidence of flares [33 vs 34%, p = 0.93] and the proportion of participants reporting positive change in quality-of-life [54 vs 44%, p = 0.27] were similar. Mean annual cost-saving was €89 and increased to €360 in those compliant to the protocol. Conclusions Telemonitoring is as safe as conventional follow-up, and reduces outpatient visits and societal costs. The positive impact on quality-of-life was similar in the two groups. This strategy is attractive for teenagers and families, and health professionals may be interested in using it to keep teenagers who are well out of hospital and ease pressure on overstretched outpatient services. Trial registration NTR3759 [Netherlands Trial Registry].
Journal of Pediatric Gastroenterology and Nutrition | 2017
Marjolijn D. Akkermans; Mirjam Vreugdenhil; Daniëlle Hendriks; Anemone van den Berg; Joachim Schweizer; Johannes B. van Goudoever; Frank Brus
Objectives: Iron deficiency (ID) in children with inflammatory bowel disease (IBD) is either an absolute (depleted iron stores) or a functional deficiency (caused by chronic inflammation). Differentiating between these 2 types of ID is important because they require a different therapeutic approach. Zinc protoporphyrin (ZPP) and red blood cell distribution width (RDW) are parameters of functional ID. Studies using these parameters to differentiate are nonexistent. We aimed to evaluate the prevalence of and risk factors for absolute and functional ID in paediatric IBD patients while using ZPP and RDW. Methods: We evaluated the iron status and medical charts of 59 paediatric IBD patients in a secondary hospital in the Netherlands. Absolute ID was defined as serum ferritin <15 &mgr;g/L in the absence of infection and/or acute inflammation (C-reactive protein <10 mg/L). Iron deficiency anaemia (IDA) was defined as absolute ID in combination with anaemia. Functional ID, in patients without absolute ID, was defined as ZPP >70 &mgr;mol/mol haem and/or an RDW >14%. Anaemia of chronic disease (ACD) was defined as functional ID in combination with anaemia. Results: Absolute and functional ID were found in 19/59 (32.2%) and 32/40 (80%) patients, respectively. The prevalence of IDA and ACD was 27.1% (16/59) and 20% (8/40), respectively. Multivariate analyses showed that absolute ID and IDA were both associated with a more recent IBD-diagnosis (both P < 0.05). Conclusions: Absolute and functional ID are common in paediatric IBD patients, and this differentiation is important because of therapeutic consequences. Furthermore, absolute ID and IDA are associated with a more recent IBD-diagnosis.
The Journal of Pediatrics | 2017
Sabine L. Vriezinga; Annelise Borghorst; Elske van den Akker-van Marle; Marc A. Benninga; Elvira K. George; Daniëlle Hendriks; Erica Hopman; Tim de Meij; Andrea E. van der Meulen-de Jong; Hein Putter; Edmond Rings; Maaike Schaart; Joachim Schweizer; Margot Smit; Merit M. Tabbers; Michel E. Weijerman; Margreet Wessels; M. Luisa Mearin
Objective To evaluate the (cost‐)effectiveness of online consultations in follow‐up of patients with celiac disease (CD). Study design Multicenter randomized, controlled trial involving 304 patients aged ≤25 years with CD for ≥1 year, randomized to an online (n = 156) or outpatient consultation (n = 148). An online consultation included questionnaires for symptom and growth measurement. Antitransglutaminase‐type‐2 antibodies were determined using a point‐of‐care (POC) test. Controls had a traditional consultation with antitransglutaminase‐type‐2 antibodies testing in laboratories. Both groups completed questionnaires concerning CD‐specific health‐related quality of life (HRQOL), gluten‐free diet adherence, and patient satisfaction. Six months later, participants repeated HRQOL and patient satisfaction questionnaires and the POC test. The primary outcome was anti‐transglutaminase‐type‐2 antibodies after 6 months, and the secondary outcomes were health problems, dietary adherence, HRQOL, patient satisfaction, and costs. Results The performance of the POC test was inferior to laboratory testing (2/156 positive POC tests vs 13/148 positive laboratory tests; P = .003). Health problems were detected significantly more frequently using online consultation. The detection of growth problems and dietary transgressions was similar. HRQOL (from 1 [good] to 5 [poor]) improved after online consultation (from 3.25 to 3.16 [P = .013] vs controls from 3.10 to 3.23; P = .810). Patient satisfaction (from 1 [low] to 10 [high]) was 7.6 (online) vs 8.0 (controls; P = .001); 58% wished to continue online consultations. Mean costs per participant during the studied period were &U20AC;202 less for the online group (P < .001). Conclusions The primary outcome could not be tested because the POC test was unreliable. Nevertheless, our results indicate that online consultations for children and young adults with CD are cost saving, increase CD‐specific HRQOL, and are satisfactory for the majority. Trial Registration Trialregister.nl: NTR3688.
Pediatric Hematology and Oncology | 2017
Marjolijn D. Akkermans; Lieke Uijterschout; Marianne Nuijsink; Daniëlle Hendriks; J.B. van Goudoever; Frank Brus
ABSTRACT Low iron stores in children, absolute iron deficiency (AID), can lead to impaired neurodevelopment and requires iron therapy. In the presence of infection/inflammation, like in cystic fibrosis (CF), serum ferritin (SF) is not a reliable biomarker for AID. Red blood cell distribution width (RDW) is a promising alternative reported not to be influenced by infection in healthy children. Currently, there are no data on the diagnostic capacity of RDW to detect AID in pediatric CF patients. This was a prospective observational study that investigated iron status biomarkers in 53 Dutch pediatric CF patients. AID was defined using World Health Organization criteria for SF in stable patients (no recent pulmonary exacerbation) and C-reactive protein (CRP) ≤10 mg/l. Patients with AID had higher RDW levels than patients without AID (p = 0.019). An RDW ≥13.2% showed the following test statistics: sensitivity 100%; specificity 39.4%; positive predictive value 20%; and negative predictive value 100%. Furthermore, we found a correlation between RDW and CRP in the total group that originated from the stable patients (r = 0.308; p = 0.042). In conclusion, the diagnostic capacity of RDW for detecting AID in pediatric CF patients seems limited because RDW levels might also be influenced by chronic infection/inflammation in these patients.
Archives of Disease in Childhood | 2012
Lieke Uijterschout; J. Vloemans; M Nuysink; Daniëlle Hendriks; Frank Brus
Background Iron deficiency (ID) is common in patients with cystic fibrosis (CF). In adult CF patients ID is related to lung disease severity and thought to be caused by chronic inflammation. Increased iron levels in sputum are associated with P. aeruginosa infections. Aim To establish the prevalence of ID and iron deficiency anemia (IDA) in children with CF and associations of ID with dietary iron intake, lung disease severity and Pseudomonas aeruginosa infection. Methods Clinical charts of 54 children with CF aged 0 to 16 were reviewed. Follow-up varied from 1 to 14 years with 346 annual observations in total. Laboratory data (hemoglobin (Hb), serum ferritin (SF)) and results of pulmonary function tests, sputum cultures and 3-day food records were collected. Results 46 children (85.2%) were iron deficient (SF<30µg/l) in at least one year and ID was present in 329 of 346 observations (95.1%). IDA (SF<30 µg/l and Hb >2SD below the mean of similarly aged children) was present in 8 observations (2.4%) in 6 patients (11.1%). Children with ID were younger (6.4 year versus 10.6 year, p=0.00) and had less pulmonary exacerbations (p=0.01). ID was not associated with FEV1, Pseudomonas aeruginosa infection or dietary iron intake. Conclusion ID is common in young children with CF and associated with less pulmonary exacerbations. We suggest that ID in these children is caused by rapid growth and accelerated erythropoies instead of disease severity or insufficient dietary iron intake.
Journal of Crohns & Colitis | 2018
G R van den Brink; Luuk Stapersma; L. E. Vlug; D. Rizopolous; A. G. Bodelier; H. van Wering; P. C. W. M. Hurkmans; R. J. L. Stuyt; Daniëlle Hendriks; J. A. T. van der Burg; Elisabeth M. W. J. Utens; J. C. Escher